Could 13C MRI assist clinical decision-making for patients with heart disease?

NMR in Biomedicine

Volumn 24, Issue 8, 2011, Pages 973-979

  Malloy, Craig R ^a,b,c   Merritt, Matthew E ^a,b   Dean Sherry, A ^a,b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c North Texas Healthcare System   (United States)

Author keywords

13C; Heart failure; Hyperpolarization; Ischemia; Metabolism; Myocardial viability

Indexed keywords

13C; HEART FAILURE; HYPERPOLARIZATION; ISCHEMIA; MYOCARDIAL VIABILITY;

CARBON DIOXIDE; CARDIOLOGY; DECISION MAKING; DISEASES; HEART; METABOLISM; PHYSIOLOGY;

PATIENT TREATMENT;

1 ALANINE C 13; 1 LACTATE C 13; 1 PYRUVATE C 13; ACETYL COENZYME A; ADENOSINE TRIPHOSPHATE; BICARBONATE C 13; DOBUTAMINE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PYRUVIC ACID; UNCLASSIFIED DRUG; CARBON; DIAGNOSTIC AGENT;

CARBON NUCLEAR MAGNETIC RESONANCE; CLINICAL DECISION MAKING; CONGESTIVE HEART FAILURE; ENZYME METABOLISM; EXERCISE ELECTROCARDIOGRAPHY; HEART DISEASE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE; HUMAN; HYPERPOLARIZATION; ISCHEMIC HEART DISEASE; NONHUMAN; PHARMACOLOGIC STRESS TESTING; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRESS ECHOCARDIOGRAPHY; VALVULAR HEART DISEASE; DECISION MAKING; HEART VENTRICLE; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING;

CARBON ISOTOPES; DECISION MAKING; HEART DISEASES; HEART VENTRICLES; HUMANS; MAGNETIC RESONANCE IMAGING; MYOCARDIUM;

EID: 80052854052     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1718     Document Type: Review

References (42)

1. 129Xe. Nature, 1994; 370: 199-201.
2. 3He gas. Magn. Reson. Med. 1995; 33: 271-275.
3. Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, Servin R, Thaning M, Golman K. Increase in signal-to-noise ratio of >10, 000 times in liquid-state NMR. Proc. Natl. Acad. Sci. USA, 2003; 100: 10 158-10 163.
4. Golman K, in't Zandt R, Thaning M. Real-time metabolic imaging. Proc. Natl. Acad. Sci. USA, 2006; 103: 11 270-11 275.
5. 13C magnetic resonance imaging for in vivo tumor diagnosis. Cancer Res. 2006; 66: 10 855-10 860.
6. Golman K, Ardenkjaer-Larsen JH, Petersson JS, Mansson S, Leunbach I. Molecular imaging with endogenous substances. Proc. Natl. Acad. Sci. USA, 2003; 100: 10 435-10 439.
7. 13C MRI. Magn. Reson. Med. 2008; 59: 1005-1013.
8. 13C. Acad Radiol. 2006; 13: 932-942.
9. 2]fumarate is a marker of cell necrosis and treatment response in tumors. Proc. Natl. Acad. Sci. USA, 2009; 106: 19 801-19 806.
10. 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res. 2008; 68: 8607-8615.
11. 13C-1-pyruvate. Magn. Reson. Med. 2007; 58: 65-69.
12. Chen AP, Albers MJ, Cunningham CH, Kohler SJ, Yen YF, Hurd RE, Tropp J, Bok R, Pauly JM, Nelson SJ, Kurhanewicz J, Vigneron DB. Hyperpolarized C-13 spectroscopic imaging of the TRAMP mouse at 3T - initial experience. Magn. Reson. Med. 2007; 58: 1099-1106.
13. 13C-labelled bicarbonate. Nature, 2008; 453: 940-943.
14. 13C magnetic resonance imaging and spectroscopy. Nat. Med. 2007; 13: 1382-1387.
15. 13C allows a direct measure of flux through a single enzyme-catalyzed step by NMR. Proc. Natl. Acad. Sci. USA, 2007; 104; 19 773-19 777.
16. -. Magn. Reson. Med. 2008; 60: 1029-1036.
17. 13C magnetic resonance spectroscopy. FASEB J. 2009; 23: 2529-2538.
18. 13C]pyruvate. Am. J. Physiol. Heart Circ. Physiol. 2010; 298: H1556-H1564.
19. Schroeder MA, Atherton HJ, Cochlin LE, Clarke K, Radda GK, Tyler DJ. The effect of hyperpolarized tracer concentration on myocardial uptake and metabolism. Magn. Reson. Med. 2009; 61: 1007-1014.
20. Schroeder MA, Cochlin LE, Heather LC, Clarke K, Radda GK, Tyler DJ. In vivo assessment of pyruvate dehydrogenase flux in the heart using hyperpolarized carbon-13 magnetic resonance. Proc. Natl. Acad. Sci. USA, 2008; 105: 12 051-12 056.
21. Lau AZ, Chen AP, Ghugre NR, Ramanan V, Lam WW, Connelly KA, Wright GA, Cunningham CH. Rapid multislice imaging of hyperpolarized (13)C pyruvate and bicarbonate in the heart. Magn. Reson. Med. 2010; 64: 1323-1331.
22. Viale A, Reineri F, Santelia D, Cerutti E, Ellena S, Gobetto R, Aime S. Hyperpolarized agents for advanced MRI investigations. Q. J. Nucl. Med. Mol. Imaging, 2009; 53: 604-617.
23. Gheorghiade M, Sopko G, De Luca L, Velazquez EJ, Parker JD, Binkley PF, Sadowski Z, Golba KS, Prior DL, Rouleau JL, Bonow RO. Navigating the crossroads of coronary artery disease and heart failure. Circulation, 2006; 114: 1202-1213.
24. Slart RH, Bax JJ, van Veldhuisen DJ, van der Wall EE, Dierckx RA, Jager PL. Imaging techniques in nuclear cardiology for the assessment of myocardial viability. Int. J. Cardiovasc. Imaging, 2006; 22: 63-80.
25. Siebelink HM, Lamb HJ. Magnetic resonance imaging for myocardial viability. EuroIntervention, 2010; 6(Suppl G): G107-G114.
26. Hickman M, Chelliah R, Burden L, Senior R. Resting myocardial blood flow, coronary flow reserve, and contractile reserve in hibernating myocardium: implications for using resting myocardial contrast echocardiography vs. dobutamine echocardiography for the detection of hibernating myocardium. Eur. J. Echocardiogr. 2010; 11: 756-762.
27. Hansen TH, Segar DS. The use of dobutamine stress echocardiography for the determination of myocardial viability. Clin. Cardiol. 1996; 19: 607-612.
28. 11C acetate in patients with old myocardial infarction. Usefulness of low-dose dobutamine infusion. Circulation, 1996; 94: 1834-1841.
29. Gropler RJ, Geltman EM, Sampathkumaran K, Pérez JE, Moerlein SM, Sobel BE, Bergmann SR, Siegel BA. Functional recovery after coronary revascularization for chronic coronary artery disease is dependent on maintenance of oxidative metabolism. J. Am. Coll. Cardiol. 1992; 20: 569-577.
30. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS, American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2008. Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 2008; 52: e1-e142.
31. Taegtmeyer H. Energy metabolism of the heart: from basic concepts to clinical applications. Curr. Probl. Cardiol. 1994; 19: 59-113.
32. Jeffrey FM, Diczku V, Sherry AD, Malloy CR. Substrate selection in the isolated working rat heart: effects of reperfusion, afterload, and concentration. Basic Res. Cardiol. 1995; 90: 388-396.
33. Jeffrey FM, Malloy CR. Respiratory control and substrate effects in the working rat heart. Biochem. J. 1992; 287: 117-123.
34. Beadle RM, Frenneaux M. Modification of myocardial substrate utilisation: a new therapeutic paradigm in cardiovascular disease. Heart, 2010; 96: 824-830.
35. Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L, Ashrafian H, Horowitz J, Fraser AG, Clarke K, Frenneaux M. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation, 2005; 112: 3280-3288.
36. Murray AJ, Edwards LM, Clarke K. Mitochondria and heart failure. Curr. Opin. Clin. Nutr. Metab. Care, 2007; 10: 704-711.
37. Abozguia K, Clarke K, Lee L, Frenneaux M. Modification of myocardial substrate use as a therapy for heart failure. Nat. Clin. Pract. Cardiovasc. Med. 2006; 3: 490-498.
38. Stanley WC, Morgan EE, Huang H, McElfresh TA, Sterk JP, Okere IC, Chandler MP, Cheng J, Dyck JR, Lopaschuk GD. Malonyl-CoA decarboxylase inhibition suppresses fatty acid oxidation and reduces lactate production during demand-induced ischemia. Am. J. Physiol. Heart Circ. Physiol. 2005; 289: H2304-H2309.
39. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation, 2008; 117: 2340-2350.
40. Bhattacharya P, Ross BD, Bünger R. Cardiovascular applications of hyperpolarized contrast media and metabolic tracers. Exp. Biol. Med. (Maywood), 2009; 234: 1395-1416.
41. Comment A, Rentsch J, Kurdzesau F, Jannin S, Uffmann K, van Heeswijk RB, Hautle P, Konter JA, van den Brandt B, van der Klink JJ. Producing over 100ml of highly concentrated hyperpolarized solution by means of dissolution DNP. J. Magn. Reson. 2008; 194: 152-155.
42. Kurhanewicz J, Vigneron DB, Brindle K, Chekmenev EY, Comment A, Cunningham CH, DeBerardinis RJ, Green GG, Leach MO, Rajan SS, Rizi RR, Ross BD, Warren WS, Malloy CR. Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. Neoplasia, 2011; 13: 81-97.